CTIC - シ―ティ―アイ・バイオファ―マ (CTI BioPharma Corp.) シ―ティ―アイ・バイオファ―マ

 CTICのチャート


 CTICの企業情報

symbol CTIC
会社名 CTI BioPharma Corp (シ―ティ―アイ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 CTIバイオファーマ(CTI BioPharma Corp. )(旧称:Cell Therapeutics Inc.)は癌を治療する毒性の少ない方法の取得・開発・商品化に焦点を当てるバイオ医薬品会社。同社は満たされていない医療ニーズのある血液関連癌向けの治療に力を集中する。同社は主に再発乗算または難治性の積極的な非ホジキンリンパ腫(NHL)のために、欧州連合でPIXUVRI(ピクサントロン)の商品化に従事する他、骨髄線維症の治療用pacritinibの第三相臨床試験を実行する。PIXUVRIは新規アザ・アントラセンジオン誘導体であり、構造的にアントラサイクリン及びアントラセンジオンに関連するが、心毒性作用の同じレベルに関連すると表示されない。   シ―ティ―アイ・バイオファ―マは、米国のバイオ医薬品会社。癌治療法の取得、開発、商業化に従事する。欧州地方で非ホジキンリンパ腫治療の「PIXUVRI(ピクサントロン)」を商品化することに焦点を当てる。血液関連癌のスペクトルをカバ―する新たな治療標的を当てるほか癌と共に生きる人々のための治療選択肢の開発も展開する。   CTI BioPharma Corp. is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
本社所在地 3101 Western Avenue Suite 600 Seattle WA 98121 USA
代表者氏名
代表者役職名
電話番号 +1 206-282-7100
設立年月日 33482
市場名 NASDAQ Small Cap
ipoyear 1997年
従業員数 149人
url www.celltherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/ctic
adr_tso
EBITDA EBITDA(百万ドル) -43.17000
終値(lastsale) 2.05
時価総額(marketcap) 118877294.2
時価総額 時価総額(百万ドル) 118.87730
売上高 売上高(百万ドル) 13.25700
企業価値(EV) 企業価値(EV)(百万ドル) 40.31630
当期純利益 当期純利益(百万ドル) -41.67700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CTI BioPharma Corp revenues decreased 52% to $11.1M. Net loss applicable to common stockholders decreased 18% to $15.4M. Revenues reflect License and contract revenue decrease of 49% to $11.1M Product sales net decrease from $1M to $0K. Lower net loss reflects Other selling general decrease of 47% to $8.4M (expense) Other non-operating income (expense) increase from $30K (expense) to $4.7M (income).

 CTICのテクニカル分析


 CTICのニュース

   The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences  2020/10/07 11:30:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Inc (NASDAQ: PRLD ) ProPhase Labs Inc (NASDAQ: PRPH ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 6) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) (reacted to negative results for a mid-stage study of lenabasum in cystic fibrosis patients) Dyne Therapeutics Inc (NASDAQ: DYN ) Outset Medical Inc (NASDAQ: OM ) Teligent Inc (NASDAQ: TLGT ) Stocks In Focus Integra LifeSciences' Preliminary Q3 Revenues Exceed Estimate Medtech company Integra Lifesciences Holdings Corp (NASDAQ: IART ) preannounced third-quarter results, expecting revenues of $368 million to $370 million, down about 2.7%, but exceeding the company's guidance provided at …
   The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation  2020/10/06 12:24:11 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) argenx SE – ADR (NASDAQ: ARGX ) (presented positive new data from a Phase 3 trial evaluating efgartigimod in patients with generalized myasthenia gravis) Ascendis Pharma A/S (NASDAQ: ASND ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) (went public Friday) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) Cytokinetics, Inc. (NASDAQ: CYTK ) (reacted to presentations at the Heart Failure Society of America virtual meeting) Eidos Therapeutics Inc (NASDAQ: EIDX ) - announced a deal to be bought by BridgeBio Pharma Inc (NASDAQ: BBIO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) Myokardia Inc (NASDAQ: MYOK ) - announced a deal to be bought by Bristol-Myers Squibb Co (NYSE: BMY ) for $13.
   58 Biggest Movers From Friday  2020/10/05 08:32:53 Benzinga
Gainers Xtant Medical Holdings, Inc. (NYSE: XTNT ) shares climbed 91.4% to close at $1.57 on Friday after the company announced the closing of debt restructuring. American Renal Associates Holdings, Inc. (NYSE: ARA ) shares climbed 66.5% to close at $11.52 after the company reported an $11.50 per share cash offer from Nautic Partners. Nano-X Imaging Ltd. (NASDAQ: NNOX ) shares gained 56.2% to close at $37.44 after the company announced it will demonstrate its novel technology and medical imaging system at RSNA 2020, which is being held from November 29th to December 5th in Chicago. Westwater Resources, Inc. (NASDAQ: WWR ) surged 49.3% to close at $4.42. IDT Corporation (NYSE: IDT ) gained 39.1% to close at $9.57 after reporting higher earnings and sales for the fourth quarter. C4 Therapeutics, Inc. (NASDAQ: CCCC ) rose 34.2% to close at $25.49 after pricing its IPO at $19 per share. ProPhase Labs, Inc. (NASDAQ: PRPH ) surged 32.1% to close at $5.15. ProPhase Labs climbed 13% on Thursday after the company announced plans to explore the acquisition of one or more CLIA accredited labs suitable for COVID-19 and other testing.
   The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut  2020/10/01 12:18:26 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PMV Pharmaceuticals Inc (NASDAQ: PMVP ) PPD Inc (NASDAQ: PPD ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 30) Abeona Therapeutics Inc (NASDAQ: ABEO ) Alector Inc (NASDAQ: ALEC ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Neos Therapeutics Inc (NASDAQ: NEOS ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Theravance Biopharma Inc (NASDAQ: TBPH ) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Amag Reportedly Pursued By Apollo's Covis Pharma AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) shares surged higher after a Bloomberg report said Apollo Management's Covis Pharma unit is in advanced talks to buy Amag.
   CTI BioPharma News: Why CTIC Stock Is Skyrocketing 104% Today  2020/09/30 19:31:22 InvestorPlace
CTI BioPharma (CTIC) news for Wednesday includes plans to submit a new drug application (NDA) sending CTIC stock soaring higher.
   The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat  2020/07/22 11:24:35 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.
   CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial  2020/06/01 11:00:00 PR Newswire
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of…
   CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4  2020/05/28 11:00:00 PR Newswire
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format. Presentation…
   CTI BioPharma Reports First Quarter 2020 Financial Results  2020/05/07 20:05:00 PR Newswire
SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a…
   Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com  2020/04/20 15:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assess
   CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial  2020/06/01 11:00:00 PR Newswire
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of…
   CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4  2020/05/28 11:00:00 PR Newswire
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format. Presentation…
   CTI BioPharma Reports First Quarter 2020 Financial Results  2020/05/07 20:05:00 PR Newswire
SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a…
   Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com  2020/04/20 15:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assess
   CTI BioPharma Announces Commencement of Rights Offering  2020/02/14 12:00:00 PR Newswire
SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シ―ティ―アイ・バイオファ―マ CTIC CTI BioPharma Corp.)

 twitter  (公式ツイッターやCEOツイッターなど)